Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04485260
Title	An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Recruitment	Unknown status
Gender	both
Phase	Phase Ib/II
Variant Requirements	Yes
Sponsors	Kartos Therapeutics, Inc.
Indications	myelofibrosis
Therapies	KRT-232 + Ruxolitinib
Age Groups:	adult \| senior
Covered Countries	USA \| POL \| ITA \| ISR \| FRA \| ESP \| DEU \| BGR \| AUS